STOCK COMPENSATION PLANS

Under the Company’s 2003 Stock Option Plan, the Company was able to grant options for up to 300,000 shares of common stock to employees, officers, directors and directors emeriti. Under the Company's 2014 Equity Incentive Plan, the Company is able to grant options and awards of restricted stock (with or without performance measures) for up to 352,366 shares of common stock to employees, officers, directors and directors emeriti. Shares issued may be purchased in the open market or may be issued from authorized and unissued shares. The exercise price of each option equals the fair market value of the Company’s common stock on the date of grant. Generally, options and restricted stock vest in 20% annual installments on each of the five anniversaries from the date of the grant, and options generally have a maximum contractual term of ten years from the date of grant. At June 30, 2017, there were 171,866 shares of common stock available which may be awarded as options or restricted stock pursuant to future grant under the 2014 Equity Incentive Plan. At June 30, 2017, there were no options available for future grant under the 2003 Stock Option Plan.

At both June 30, 2017 and 2016, there were no unvested restricted stock grant shares. There were no restricted stock grants awarded during the nine months ended June 30, 2017 and 2016.

Stock option activity for the nine months ended June 30, 2017 and 2016 is summarized as follows:



	Nine Months Ended June 30, 2017				Nine Months Ended June 30, 2016
	Number of Shares		Weighted Average Exercise Price		Number of Shares		Weighted Average Exercise Price
Options outstanding, beginning of period	373,130		$	9.82	341,300		$	8.73
Exercised	(39,810	)	6.65		(16,220	)	7.88
Forfeited	(4,950	)	6.28		(2,900	)	9.96
Options outstanding, end of period	328,370		$	10.26	322,180		$	8.76

The aggregate intrinsic value of options exercised during the nine months ended June 30, 2017 and 2016 was $545,000 and $82,000, respectively.

At June 30, 2017, there were 201,100 unvested options with an aggregate grant date fair value of $393,000, all of which the Company assumes will vest. The aggregate intrinsic value of unvested options at June 30, 2017 was $2.79 million. There were 48,600 options with an aggregate grant date fair value of $111,000 that vested during the nine months ended June 30, 2017.

At June 30, 2016, there were 211,200 unvested options with an aggregate grant date fair value of $457,000. There were 48,600 options with an aggregate grant date fair value of $111,000 that vested during the nine months ended June 30, 2016.

Additional information regarding options outstanding at June 30, 2017 is as follows:



	Options Outstanding				Options Exercisable
Range of Exercise Prices ($)	Number	Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Years)	Number	Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Years)
$ 4.01 - 4.55	10,200	$	4.27	3.4	10,200	$	4.27	3.4
5.86 - 6.00	40,800	5.93		5.3	29,000	5.94		5.3
9.00	83,000	9.00		6.3	44,600	9.00		6.3
10.26 - 10.71	139,370	10.58		7.8	43,470	10.54		7.6
15.67	55,000	15.67		9.3	—	N/A		N/A
	328,370	$	10.26	7.5	127,270	$	8.45	6.6

The aggregate intrinsic value of options outstanding at June 30, 2017 and 2016 was $4.93 million and $2.01 million, respectively.

Compensation expense during the nine months ended June 30, 2017 and 2016 for all stock-based plans was as follows (dollars in thousands):



	Nine Months Ended June 30,
	2017			2016
Stock options	$	271		$	123
Less: related tax benefit recognized	(153		)	(9		)
Total	$	118		$	114

As of June 30, 2017, unrecognized compensation cost related to non-vested stock options was $305,000, which is expected to be recognized over a weighted average life of 1.85 years.